Provided by Tiger Trade Technology Pte. Ltd.

Aclaris Therapeutics

6.41
+0.08001.26%
Pre-market: 6.700.2900+4.52%07:49 EDT
Volume:2.21M
Turnover:14.18M
Market Cap:943.54M
PE:-10.94
High:6.50
Open:6.36
Low:6.29
Close:6.33
52wk High:6.52
52wk Low:1.74
Shares:147.20M
Float Shares:110.00M
Volume Ratio:1.50
T/O Rate:2.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5861
EPS(LYR):-0.5300
ROE:-59.10%
ROA:-28.98%
PB:7.57
PE(LYR):-12.09

Loading ...

Damora Therapeutics names Brian Burkavage principal financial officer, accounting officer

Reuters
·
May 05

Aclaris Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview

Reuters
·
May 04

JTL Industries Wins ACRS Nod, Tightens Grip on Global Structural Steel Markets

TIPRANKS
·
May 04

Aclaris Therapeutics Is Maintained at Outperform by Wedbush

Dow Jones
·
Apr 30

Aclaris Therapeutics price target raised to $10 from $8 at Wedbush

TIPRANKS
·
Apr 29

Wedbush Raises Price Target on Aclaris Therapeutics to $10 From $8, Keeps Outperform Rating

MT Newswires Live
·
Apr 29

Aclaris Therapeutics’ ATI-052 antibody shows PK efficacy in Phase 1a trial

TIPRANKS
·
Apr 28

BRIEF-Aclaris Therapeutics Says Positive Full Top Line Results From Phase 1A Clinical Trial Of ATI-055

Reuters
·
Apr 28

Aclaris Therapeutics Inc - Enrollment Ongoing in Phase 1B Trials of ATI-052; Top Line Results Expected H2 2026

THOMSON REUTERS
·
Apr 28

Aclaris Therapeutics Inc - ATI-052 Well Tolerated With Favorable Safety Profile in Phase 1a Trial

THOMSON REUTERS
·
Apr 28

Aclaris Therapeutics Inc: No Impact of Anti-Drug Antibodies (Ada) on Pk or Pd Has Been Observed in This Trial

THOMSON REUTERS
·
Apr 28

BML Capital’s Braden Leonard sells 300,000 Aclaris shares for $1.36 million

Reuters
·
Apr 28

Aclaris to release Phase 1a ATI-052 trial results April 28

Reuters
·
Apr 28

Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026

GlobeNewswire
·
Apr 28

Aclaris Therapeutics announces upcoming annual shareholder meeting

Reuters
·
Apr 23

Aclaris Therapeutics (ACRS) Gets a Buy from Craig-Hallum

TIPRANKS
·
Apr 17

Oppenheimer Initiates Aclaris Therapeutics at Outperform With $10 Price Target

MT Newswires Live
·
Apr 16

Aclaris Therapeutics Inc : Oppenheimer Initiates Coverage With Outperform Rating; Price Target $10

THOMSON REUTERS
·
Apr 16

Aclaris Therapeutics Initiated at Outperform by Oppenheimer

Dow Jones
·
Apr 16

U.S. RESEARCH ROUNDUP-CME Group, M&T Bank, PNC Financial Services

Reuters
·
Apr 16